<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601353</url>
  </required_header>
  <id_info>
    <org_study_id>ED1001</org_study_id>
    <nct_id>NCT01601353</nct_id>
  </id_info>
  <brief_title>Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction</brief_title>
  <official_title>Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tissue Genesis, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tissue Genesis, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of adipose derived cells for
      the treatment of erectile dysfunction symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is being conducted to determine the safety and efficacy of injecting autologous
      adipose derived cells into the penis of men with erectile dysfunction. Subjects will be
      randomized into a treatment and control arm.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events that occur during or after the procedure to measure safety and tolerability</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Erectile function</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continence</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment assessment</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erection hardness</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of adipose derived cells into penis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention through 9 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tissue Genesis Cell Isolation System</intervention_name>
    <description>Liposuction followed by injection of autologous adipose derived cells</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men aged 40 - 70

          2. Willing and able to provide written informed consent

          3. Chronic, organic erectile dysfunction (ED), duration at least 0.5 years, with baseline
             International Index of Erectile Function - Erectile Function (IIEF-EF) score of &lt; 26

          4. Willing to complete questionnaires

          5. Involved in a monogamous, heterosexual relationship for at least 3 months with both
             partners motivated to have or attempt sexual intercourse at least 4 times per month
             beginning two weeks after study treatment (subject reported)

          6. Not interested or able to use oral PDE-5 inhibitor (PDE-5i) drug therapy, and willing
             to forgo these treatments for the first 6-month period following study treatment (in
             addition may include a minimum 4-week washout since last PDE-5i use prior to
             completion of the baseline erectile function assessments and study treatment)

          7. Willing to limit alcohol intake and eliminate use of recreational drugs for sexual
             encounters

          8. Willing to undergo a minor surgical procedure and injection

          9. Abdominal area amenable to liposuction of at least 60-120 cc of adipose tissue based
             on Investigator examination

         10. Mentally competent and able to understand all study requirements (based on
             investigator assessment)

         11. Willing to be available for all baseline, treatment and follow-up examinations
             required by protocol

         12. Willing to forego participation in any other study throughout the duration of this
             study unless receiving prior approval by Sponsor.

        Exclusion Criteria:

          1. Evidence of prostate cancer which requires additional radiotherapy or other adjuvant
             therapy

          2. Previous pelvic or abdominal radiation therapy

          3. Previous, concomitant or scheduled use of anti-androgen therapy

          4. Untreated hypogonadism or low serum total testosterone (&lt; 200 ng/dL)

          5. Clinically evident penile anatomical deformities (e.g., Peyronie's disease) or history
             of priapism

          6. Skin irritation, infection, wound, sore or disruption in the immediate areas of skin
             entry for abdominal liposuction or penile injection (including abdominal trauma and
             abdominal skin cancer (basal cell carcinoma, squamous cell carcinoma, and melanoma))

          7. Use of any non-study treatment for erectile dysfunction within 4 weeks of study
             treatment and a lack of willingness to continue through 6 months after study treatment

          8. Any previous penile implant or penile vascular surgery

          9. Current or previous malignancy other than localized prostate cancer or nonabdominal,
             non-melanoma skin cancer (successfully treated or treatable by curative excision or
             other local curative therapy- abdominal skin cancer is exclusionary as indicated in
             criteria 6)

         10. Uncontrolled hypertension or hypotension (systolic blood pressure &gt; 170 or &lt; 90 mm Hg,
             and diastolic blood pressure &gt; 100 or &lt; 50 mm Hg)

         11. Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction
             within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart
             failure) or symptomatic postural hypotension within 6 months before screening

         12. Hemoglobin A1c &gt; 8% within 8 weeks prior to study treatment

         13. Current urinary tract or bladder infection

         14. Drug, alcohol, or substance abuse reported within the last three years (subject
             reported)

         15. Subject's sexual partner is &lt; 18 years of age, nursing, or known to be pregnant at
             screening, or wishes to become pregnant during the study period, or has any
             gynecologic problems, major medical conditions, or other factors that would limit
             participation in sexual intercourse to less than 4 times per month (subject reported)

         16. Weight less than 154 lbs/ 70 kg, or BMI â‰¥ 30

         17. Unable to limit or avoid nonsteroidal anti-inflammatory drugs(NSAIDs) for 15 days
             prior to treatment (subject reported)

         18. Bleeding or clotting disorder, use of anticoagulant therapy, or history of easy or
             excessive bruising

         19. Lab values for Complete Blood Count(CBC), Prothrombin Time(PT)/Partial Thromboplastin
             Time(PTT)/International Normalized Ration(INR), liver function and creatinine falling
             outside the normal lab values (see section 5.3 for further detail)

         20. Systemic autoimmune disorder

         21. Significant active systemic or localized infection

         22. Receiving immunosuppressant medications
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Diego Sexual Medicine</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

